Peripheral Artery Disease in Men. The Leg Symptom That Signals a Heart Problem.

Peripheral artery disease is atherosclerosis of the arteries supplying the legs, and it is not a local problem. A man with PAD carries three to four times the cardiovascular mortality risk of a man the same age without it, because the plaque blocking his femoral artery is the same process blocking his coronary and cerebral vessels. 5 / Solid

The Mechanism

Atherosclerosis is a systemic disease of large and medium arteries. The same inflammatory and lipid-driven plaque formation that narrows the coronary arteries also affects the aorta, the iliac arteries, the femoral and popliteal arteries, and the tibial vessels supplying the foot. PAD represents this process in the lower extremity circulation; it is not a separate disease with a different cause.

The physiological consequence is reduced oxygen delivery to exercising lower limb muscle. At rest, collateral vessels and baseline cardiac output are often sufficient to maintain perfusion, so the patient is asymptomatic or mildly symptomatic. With exertion, the oxygen demand of working muscle increases sharply. When arterial stenosis limits flow below the level needed to meet this demand, the ischemic muscle produces cramping, heaviness, or pain. This is claudication: the defining symptom of moderate PAD.

The pattern of claudication corresponds to the anatomical level of obstruction. Aortoiliac disease (Leriche syndrome) produces buttock and thigh claudication with, in men, erectile dysfunction from inadequate pelvic arterial flow. Femoropopliteal disease, the most common location in smokers, produces calf claudication. Infrapopliteal tibial disease produces foot and calf symptoms and is particularly common in diabetics.

As disease severity progresses, the resting perfusion pressure falls below the threshold needed to maintain tissue viability without exertion. This produces rest pain, typically in the foot at night, relieved by hanging the foot off the bed to allow gravity-assisted flow. Beyond rest pain is critical limb ischemia: non-healing wounds and tissue loss. The Rutherford classification grades PAD from grade I (asymptomatic) through grade VI (major tissue loss).

The risk factor profile for PAD is nearly identical to that for coronary artery disease, with one important difference: smoking is a substantially stronger independent risk factor for PAD than for coronary disease. The Edinburgh Artery Study, following 1,592 men and women aged 55 to 74, found that current smoking conferred an odds ratio of approximately 3.7 for PAD compared to never-smokers. Diabetes multiplies the risk further and, through neuropathy, can render the symptom of claudication absent even with severe arterial obstruction.

What the Evidence Shows

PAD affects approximately 8 to 12 million Americans, according to the Hirsch et al. 2006 JAHA review. Prevalence increases from roughly 3 percent in adults under age 60 to greater than 20 percent in adults over age 75. Men develop symptomatic PAD earlier than women, and the disparity in smoking prevalence by sex accounts for a significant portion of this difference in earlier cohorts.

The cardiovascular mortality signal from PAD is well established. The REACH Registry, enrolling 67,888 patients with established or high-risk atherosclerotic disease, found that PAD patients had cardiovascular event rates comparable to or exceeding those of patients with established coronary artery disease. One-year rates of MI, stroke, and cardiovascular death in patients with symptomatic PAD were 5.35 percent in the REACH analysis. The ankle-brachial index (ABI) itself functions as a continuous cardiovascular risk marker: every 0.10-unit decrease in ABI below 1.0 is associated with incrementally higher cardiovascular event rates.

The ankle-brachial index measures the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. Normal ABI is 1.0 to 1.4. ABI below 0.9 confirms PAD with a specificity exceeding 95 percent in most validation studies. ABI in the 0.7 to 0.9 range indicates mild to moderate disease with preserved resting perfusion. ABI below 0.5 indicates severe disease, often with rest pain or tissue risk. ABI above 1.4 is falsely elevated in patients whose vessel walls are calcified and incompressible, most often in long-standing diabetics; toe-brachial index or pulse volume recordings are used in this population instead.

The ABI measurement takes 15 minutes in a clinical office using blood pressure cuffs at the arm and ankle and a handheld Doppler probe. It is non-invasive, inexpensive, and covered by insurance when clinically indicated. It is also substantially underutilized as a cardiovascular risk assessment tool, particularly in primary care settings.

For treatment of claudication, supervised exercise training has the strongest evidence base among non-invasive interventions. Multiple randomized trials and the 2005 AHA Scientific Statement on PAD established that structured treadmill walking programs, typically three sessions per week for 12 weeks with each session pushing to near-maximal claudication pain followed by brief rest, improve pain-free walking distance by 50 to 200 percent and functional capacity comparably to or better than angioplasty in stable claudication populations.

The mechanism of benefit involves multiple adaptations: improved skeletal muscle oxidative enzyme capacity, enhanced oxygen extraction efficiency, and possibly some degree of collateral vessel remodeling. Supervised programs are substantially more effective than instruction to exercise without formal supervision: the CLEVER trial, published in Circulation in 2011 and enrolling 119 patients, found supervised exercise superior to stent revascularization at 6 months for peak walking performance in aortoiliac PAD.

What to Do This Week

1. If you have leg pain, cramping, or heaviness that occurs predictably during walking and resolves within minutes of stopping, describe this symptom precisely to your physician and request an ABI measurement. The key features that distinguish claudication from musculoskeletal pain or venous insufficiency are its reproducibility at the same walking distance and its complete resolution with rest. Use those words: “It starts at the same point every time and goes away when I stop.”

2. If you have diabetes and a smoking history and have not had an ABI measured, ask for it at your next visit. Diabetic neuropathy masks the pain signal of claudication, so PAD in diabetics is frequently asymptomatic until ulceration or gangrene occurs. An ABI below 0.9 in a patient without symptoms is still an independent cardiovascular risk marker requiring statin therapy, antiplatelet therapy, and aggressive risk factor modification. It is also a signal to examine the feet at every clinical encounter for early ulceration.

3. If you have confirmed PAD and you still smoke, cessation is the single intervention with the greatest effect on both PAD progression and overall cardiovascular mortality. Continued smoking after PAD diagnosis doubles the rate of progression to critical limb ischemia. Varenicline (Chantix), bupropion, and nicotine replacement therapy are all available with documented efficacy. Ask for a cessation prescription, not a referral to a pamphlet.

4. If you have PAD, confirm that you are on statin therapy and antiplatelet therapy. The Heart Protection Study, enrolling 20,536 high-risk patients including those with PAD, showed that simvastatin reduced major cardiovascular events by 24 percent in PAD patients regardless of baseline LDL. Antiplatelet therapy with aspirin or clopidogrel reduces cardiovascular events in PAD populations. Both are standard of care in symptomatic PAD and should be confirmed at every clinical visit.

5. Ask whether a referral to a supervised exercise program is available in your area. Medicare covers supervised exercise therapy for PAD since 2017, and most commercial insurers follow Medicare coverage policies. If a formal program is not available, ask your physician for a structured walking protocol specifying frequency, duration, and the instruction to walk to near-maximal pain before resting and repeating.

The Systemic Vascular Picture

A PAD diagnosis requires thinking beyond the leg. The same atherosclerotic process responsible for an ABI of 0.7 in the femoral circulation is operating in the coronary and carotid circulations simultaneously. Most patients with PAD have subclinical or established coronary artery disease. The PARTNERS study, published in JAMA in 2001 and screening 6,979 primary care patients aged 70 or older, found that among patients with newly identified PAD, 68.7 percent had pre-existing cardiovascular disease or significant cardiovascular risk factors that had not been fully addressed.

The implication is practical: a new PAD diagnosis is the trigger for a systematic cardiovascular risk assessment, not just a treatment plan for leg symptoms. Statin intensification to an ApoB target below 70 mg/dL (or below 55 mg/dL if atherosclerotic disease is present in multiple territories), antiplatelet therapy, blood pressure control, smoking cessation, and diabetes management all apply simultaneously. The leg symptoms are the presenting complaint; the cardiovascular risk reduction program is the treatment.

Drug Therapy: What the Evidence Supports

Beyond supervised exercise, three pharmacological interventions have strong evidence in PAD:

Statin therapy is the most important pharmacological intervention for PAD at a systemic level. As noted above, the Heart Protection Study demonstrated 24 percent relative risk reduction in major cardiovascular events in PAD patients on simvastatin. The evidence base applies regardless of baseline LDL concentration: PAD patients benefit from statin therapy at any starting LDL level. The 2016 ACC/AHA guidelines give statin therapy in PAD a Class I recommendation with Level A evidence. ApoB should be the treatment target, with a goal below 70 mg/dL in high-risk primary prevention and below 55 mg/dL in patients with established disease in multiple vascular territories.

Antiplatelet therapy reduces the rate of MI, stroke, and vascular death in symptomatic PAD. The CAPRIE trial, enrolling 19,185 patients with recent ischemic events or symptomatic PAD, found that clopidogrel (75 mg daily) reduced the combined endpoint of ischemic stroke, MI, and vascular death by 8.7 percent relative to aspirin. For most symptomatic PAD patients, either aspirin (75 to 325 mg daily) or clopidogrel (75 mg daily) is appropriate antiplatelet monotherapy. The choice between them depends on concomitant conditions and tolerability.

Cilostazol is an oral phosphodiesterase-3 inhibitor approved for the treatment of intermittent claudication. In multiple randomized trials, cilostazol improved pain-free walking distance by approximately 50 percent relative to placebo and improved quality of life measures. It is contraindicated in patients with heart failure of any severity (a meaningful restriction given the cardiovascular comorbidity burden in this population). Where contraindications are absent, cilostazol is a reasonable addition for patients with claudication who are not achieving adequate improvement with supervised exercise alone.

Rivaroxaban plus aspirin (the COMPASS regimen) deserves specific mention for PAD patients. The COMPASS trial, enrolling 27,395 patients with stable coronary or peripheral artery disease, found that rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily reduced major cardiovascular events by 24 percent compared to aspirin alone. In the PAD subgroup specifically, the combination also reduced major adverse limb events, including amputation, by 46 percent. This is a clinically important finding: anticoagulant-antiplatelet combination therapy improved both systemic cardiovascular outcomes and limb-specific outcomes in PAD patients at acceptable bleeding cost. The 2021 ACC/AHA PAD guidelines give this regimen a Class IIa recommendation for patients with symptomatic PAD who are not at high bleeding risk.

When Medical Therapy Is Not Enough

Revascularization in PAD is reserved for defined indications where medical therapy and supervised exercise have been improved and found insufficient. The indications are:

Rest pain (Rutherford grade III) with confirmed hemodynamic insufficiency.

Tissue loss: non-healing wounds, ulceration, or gangrene with documented ischemic etiology (critical limb-threatening ischemia, CLTI).

Lifestyle-limiting claudication that has not responded to an adequate trial (minimum 3 months) of maximally dosed claudication therapy and structured exercise.

Revascularization options include endovascular approaches (balloon angioplasty, drug-coated balloon angioplasty, bare-metal or drug-eluting stenting) and open surgical approaches (bypass grafting using vein or prosthetic conduit). The anatomical location and extent of disease, the patient’s surgical risk, and the availability of conduit determine which approach is preferred.

For aortoiliac disease, endovascular therapy with stenting has excellent long-term patency and is the preferred first approach for most lesions. For femoropopliteal disease, drug-coated balloon angioplasty has superior patency compared to plain balloon angioplasty in lesions of appropriate length, and is now standard in many centers. For infrapopliteal disease in critical limb ischemia, bypass to tibial or pedal vessels using autogenous vein provides the best long-term results when conduit is available.

The BEST-CLI trial, published in the NEJM in 2022, enrolled 1,830 patients with chronic limb-threatening ischemia randomized to endovascular or surgical revascularization. In patients with an adequate single-segment great saphenous vein available for bypass, open surgery produced superior event-free survival (freedom from major amputation or death) compared to endovascular therapy. In patients without adequate saphenous vein, outcomes were equivalent between the two approaches. This trial has substantially influenced how the field approaches revascularization decisions in CLTI.

PAD is a visible, measurable sign of arterial disease that has been progressing for years. The ABI test that identifies it costs nothing material and takes 15 minutes. In a clinical setting where cardiovascular events are largely preventable when detected and treated early, PAD is one of the clearest opportunities to intervene before the coronary or cerebrovascular event that the same plaque burden is building toward.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.